187 related articles for article (PubMed ID: 8077916)
21. Receptor usage and differential downregulation of CD46 by measles virus wild-type and vaccine strains.
Schneider-Schaulies J; Schnorr JJ; Brinckmann U; Dunster LM; Baczko K; Liebert UG; Schneider-Schaulies S; ter Meulen V
Proc Natl Acad Sci U S A; 1995 Apr; 92(9):3943-7. PubMed ID: 7732009
[TBL] [Abstract][Full Text] [Related]
22. Productive measles virus brain infection and apoptosis in CD46 transgenic mice.
Evlashev A; Moyse E; Valentin H; Azocar O; Trescol-Biémont MC; Marie JC; Rabourdin-Combe C; Horvat B
J Virol; 2000 Feb; 74(3):1373-82. PubMed ID: 10627548
[TBL] [Abstract][Full Text] [Related]
23. Is mRNA and protein level of CD46 altered in measles virus vaccine strain S191-infected cells?
Hu C; Qi Y; Zhang P; Liu X; Xu Q; Chen X
Biochem Biophys Res Commun; 2004 Sep; 322(3):794-802. PubMed ID: 15336534
[TBL] [Abstract][Full Text] [Related]
24. High expression of membrane cofactor protein of complement (CD46) in human leukaemia cell lines: implication of an alternatively spliced form containing the STA domain in CD46 up-regulation.
Hara T; Suzuki Y; Semba T; Hatanaka M; Matsumoto M; Seya T
Scand J Immunol; 1995 Dec; 42(6):581-90. PubMed ID: 8552981
[TBL] [Abstract][Full Text] [Related]
25. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing.
Russell SM; Sparrow RL; McKenzie IF; Purcell DF
Eur J Immunol; 1992 Jun; 22(6):1513-8. PubMed ID: 1601037
[TBL] [Abstract][Full Text] [Related]
26. CD46 transgene expression in pig peripheral blood mononuclear cells does not alter their susceptibility to measles virus or their capacity to downregulate endogenous and transgenic CD46.
Schneider-Schaulies J; Martin MJ; Logan JS; Firsching R; ter Meulen V; Diamond LE
J Gen Virol; 2000 Jun; 81(Pt 6):1431-8. PubMed ID: 10811926
[TBL] [Abstract][Full Text] [Related]
27. Interaction of measles virus (Hallé strain) with CD46: evidence that a common binding site on CD46 facilitates both CD46 downregulation and MV infection.
Lecouturier V; Rizzitelli A; Fayolle J; Daviet L; Wild FT; Buckland R
Biochem Biophys Res Commun; 1999 Oct; 264(1):268-75. PubMed ID: 10527876
[TBL] [Abstract][Full Text] [Related]
28. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.
Hallak LK; Merchan JR; Storgard CM; Loftus JC; Russell SJ
Cancer Res; 2005 Jun; 65(12):5292-300. PubMed ID: 15958576
[TBL] [Abstract][Full Text] [Related]
29. Expression of human complement regulatory protein CD46 restricts measles virus replication in mouse macrophages.
Korte-Sarfaty J; Pham VD; Yant S; Hirano A; Wong TC
Biochem Biophys Res Commun; 1998 Aug; 249(2):432-7. PubMed ID: 9712714
[TBL] [Abstract][Full Text] [Related]
30. Measles virus targets DC-SIGN to enhance dendritic cell infection.
de Witte L; Abt M; Schneider-Schaulies S; van Kooyk Y; Geijtenbeek TB
J Virol; 2006 Apr; 80(7):3477-86. PubMed ID: 16537615
[TBL] [Abstract][Full Text] [Related]
31. Measles virus recognizes its receptor, CD46, via two distinct binding domains within SCR1-2.
Manchester M; Gairin JE; Patterson JB; Alvarez J; Liszewski MK; Eto DS; Atkinson JP; Oldstone MB
Virology; 1997 Jun; 233(1):174-84. PubMed ID: 9201227
[TBL] [Abstract][Full Text] [Related]
32. Efficient major histocompatibility complex class II-restricted presentation of measles virus relies on hemagglutinin-mediated targeting to its cellular receptor human CD46 expressed by murine B cells.
Gerlier D; Trescol-Biémont MC; Varior-Krishnan G; Naniche D; Fugier-Vivier I; Rabourdin-Combe C
J Exp Med; 1994 Jan; 179(1):353-8. PubMed ID: 8270880
[TBL] [Abstract][Full Text] [Related]
33. Cell surface activation of the alternative complement pathway by the fusion protein of measles virus.
Devaux P; Christiansen D; Plumet S; Gerlier D
J Gen Virol; 2004 Jun; 85(Pt 6):1665-1673. PubMed ID: 15166451
[TBL] [Abstract][Full Text] [Related]
34. Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46.
Iwata K; Seya T; Yanagi Y; Pesando JM; Johnson PM; Okabe M; Ueda S; Ariga H; Nagasawa S
J Biol Chem; 1995 Jun; 270(25):15148-52. PubMed ID: 7541036
[TBL] [Abstract][Full Text] [Related]
35. Analysis of receptor (CD46, CD150) usage by measles virus.
Erlenhöfer C; Duprex WP; Rima BK; Ter Meulen V; Schneider-Schaulies J
J Gen Virol; 2002 Jun; 83(Pt 6):1431-1436. PubMed ID: 12029158
[TBL] [Abstract][Full Text] [Related]
36. Receptor (CD46)- and replication-mediated interleukin-6 induction by measles virus in human astrocytoma cells.
Ghali M; Schneider-Schaulies J
J Neurovirol; 1998 Oct; 4(5):521-30. PubMed ID: 9839649
[TBL] [Abstract][Full Text] [Related]
37. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.
Ayala-Breton C; Russell LO; Russell SJ; Peng KW
J Virol; 2014 Aug; 88(15):8332-9. PubMed ID: 24829351
[TBL] [Abstract][Full Text] [Related]
38. V domain of human SLAM (CDw150) is essential for its function as a measles virus receptor.
Ono N; Tatsuo H; Tanaka K; Minagawa H; Yanagi Y
J Virol; 2001 Feb; 75(4):1594-600. PubMed ID: 11160657
[TBL] [Abstract][Full Text] [Related]
39. Infection of chicken embryonic fibroblasts by measles virus: adaptation at the virus entry level.
Escoffier C; Gerlier D
J Virol; 1999 Jun; 73(6):5220-4. PubMed ID: 10233992
[TBL] [Abstract][Full Text] [Related]
40. CD46 short consensus repeats III and IV enhance measles virus binding but impair soluble hemagglutinin binding.
Devaux P; Buchholz CJ; Schneider U; Escoffier C; Cattaneo R; Gerlier D
J Virol; 1997 May; 71(5):4157-60. PubMed ID: 9094700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
